The FDA approved pembrolizumab plus belzutifan as an adjuvant treatment for adults with high-risk clear cell renal cell carcinoma after surgery, Dana-Farber said via the approval announcement summarized by the provided content. The regimen pairs a standard immune checkpoint inhibitor with a hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor. The move adds a new option for post-nephrectomy or post-partial nephrectomy settings where recurrence risk remains high and where the balance between efficacy and tolerability is critical. Clinicians will now weigh the combo against existing adjuvant standards and toxicity profiles. For pipeline strategists, the approval also reinforces continued combination development that targets tumor oxygen-sensing pathways alongside immune activation.